Abstract:Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. Methods Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. Findings The discovery cohort comprised 385 patients (mean age 63.6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60.7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0.90 and corresponding negative predictive value of 0.91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85.7 mL (95% CI 6.9 to 164.4) and those with a high-risk signature experienced an FVC change of -227.1 mL (-286.7 to -167.5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. Interpretation 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

The natural history of progressive fibrosing interstitial lung diseases

Real-world Experience of Nintedanib Therapy in Idiopathic-inflammatory-myopathy-related Interstitial Lung Disease: Efficacy and Tolerability

Predictors of Progression in Idiopathic Inflammatory Myopathies with Interstitial Lung Disease

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Progression of fibrosing interstitial lung disease

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

Fibrosing interstitial lung diseases: knowns and unknowns

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

Proportion and predictors of FVC decline in patients with interstitial lung disease

Lung function trajectory in progressive fibrosing interstitial lung disease

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Diagnosis and Management of Fibrotic Interstitial Lung Diseases

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

Prevalence and predictors of response to long-term treatment in patients with idiopathic pulmonary fibrosis (IPF).

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry